Balázs Győrffy. Scientific advisor 
Semmelweis University. Website
Faculty of Medicine. 2nd Department of Paediatrics. Tuzolto u. 7-9, 1094, Budapest, Hungary
Reseach subject
Oncology biomarkers capable to predict survival and therapy response
Summary
Establishing reliable personalized cancer therapy is one of the most important health research challenges. Although thousands of genes have been proposed as cancer biomarkers, most have failed in the clinical setting. The most probable reason for this is the use of rather small sample sizes for the identification and validation of candidate markers. To identify relevant markers, we will need robust sample numbers and to restrict candidates to those where a direct link between the gene and indication is confirmed. In our group we work on a truly translational study aiming to make findings from basic science useful for clinical application. In this sense, we set up genome-level databases where clinical records and expression and mutation data are integrated. To enable straightforward exploitation of the data, we develop a set of new bioinformatic tools. The strongest hits are assessed in cell culture models to discriminate driver and passenger genes. Finally, the most robust markers are evaluated in a cohort of clinical samples. Primary focus is on identifying predictive markers for breast and lung cancer and prognostic markers for breast, ovarian, colon and lung cancer.
Publications
- Győrffy B*, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients, BREAST CANCER RESEARCH AND TREATMENT 2010; 123: (3) pp. 725-731.
- Győrffy B*, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L: Multigene prognostic tests in breast cancer: past, present, future, BREAST CANCER RESEARCH 2015; 17: Paper 11. 7 p.
- Pongor L, Kormos M, Hatzis C, Pusztai L, Szabo A, Győrffy B*: A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients, GENOME MEDICINE 2015;7: (1) Paper 104. 11 p
- Magnani L, Stoeck A, Zhang X, Lánczky A, Mirabella AC, Wang T-L, Lupien M*, Győrffy B*: Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2013; 110: (16) pp. E1490-E1499.
- Mihály Zs, Kormos M, Lánczky A, Dank M, Budczies J, Szász AM, Győrffy B*. A meta-analysis of gene expression based biomarkers predicting outcome after tamoxifen treatment in breast cancer. BREAST CANCER RES TREAT, 2013 Jul;140(2):219-32.